Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Mar;63(3):454-63.

[Current status of gene therapy clinical studies for renal cell carcinoma]

[Article in Japanese]
Kenzaburo Tani  1
Affiliations
  • PMID: 15773345
Review

[Current status of gene therapy clinical studies for renal cell carcinoma]

[Article in Japanese]
Kenzaburo Tani. Nihon Rinsho. 2005 Mar.

Abstract

Renal cell carcinoma (RCC) has been considered to be one of the immunogenic cancers. There have been published many reports on immune therapy of RCC including 16 immune gene therapy protocols in USA. We have been involved in Phase I clinical trial of immune gene therapy of RCC using GM-CSF(granulocyte macrophage colony stimulating factor) gene-transduced autologous RCC(GVAX-RCC) since 1998. Our results on four stage TV RCC patients demonstrated the safety of this gene therapy. Immunological data suggested the induction of antitumor immune responses by GVAX-RCC. Addition of low dose interleukin-2 (IL-2) was considered to helpful to enhance clinical antitumor response after the vaccinations. Two out of four patients who received GVAX-RCC and low dose IL-2 have been followed up in outpatient clinic for 5.5 years and 4 years, respectively, at PS 0. Based on our clinical study results, new immune gene therapy of RCC combining dendritic cells has been studied in preclinical level.

PubMed Disclaimer

Similar articles

See all similar articles

MeSH terms

Substances

LinkOut - more resources